Peptides pulmonary delivery

A Adjei, J Garren. Pulmonary delivery of peptide drugs effect of particle size on bioavailability of... 

J. S. Patton and R. M. Platz, Routes of drug delivery case studies (2) pulmonary delivery of peptides and proteins for systemic action, Adv. Drug Deliv. Rev, 8, 179 (1992). 

Dry powder inhalers have initially found their application in inhalation therapy as a CFC-free alternative for the older MDIs. However, nowadays they seem to have a much larger potential [14,53], because of the high lung deposition that can be attained and also because they are suitable for the pulmonary delivery of therapeutic peptides and proteins [2,10,16]. 

ITABLE 13.12. Aerosolized proteins and peptides tested in humans with portable devices for pulmonary delivery... 

Pulmonary administration of PNAs has great potential for the same reasons that pulmonary protein and peptide delivery have been successful. Predominantly, the distance for transport and ease of administration of agents are the advantages of pulmonary delivery, but the formulation of labile molecules for eventual pulmonary administration as lipid-based aerosols may be problematic. 

One of the main drivers for the development of new pulmonary drug delivery systems has been the potential for noninvasive systemic delivery of protein and peptide compounds. The systemic delivery of macromolecules via the airways would overcome the inconvenience and cost associated with current methods of administration (injection), and appears likely given the large surface area of the airways and the thin pulmonary epithelium. Most research has concentrated on pulmonary delivery of insulin for the treatment of diabetes. Recently, one insulin product has completed phase three studies and is now undergoing review by European regulatory agencies for marketing approval. 

Irngartinger, M., Camuglia, V., Damm, M., Goede, J., and Frijlink, H. W. (2004) Pulmonary delivery of therapeutic peptides via dry powder inhalation Effects of micronisation and manufacturing). 

Biopharmaceutical Challenges Pulmonary Delivery of Proteins and Peptides... 

Several pharmaceutical and physiological barriers must be overcome for the successful pulmonary delivery of peptide and protein drugs [3], For example, many of these macromolecular drugs have relatively low permeability when they are administered without any absorption enhancers [4], Furthermore, the clinical toxicology of peptides/proteins in the lung, especially for chronic disease, should be of some concern [6], Therefore, cost-benefit ratios should be evaluated in the... 

Table 9.1 Summary of peptide and proteins used for pulmonary delivery.

In this chapter, we will discuss the biophysical basis and recent advances in pulmonary delivery of peptides and proteins. 

Mechanism of Peptide Absorption after Pulmonary Delivery... 

BiopharmaceuticaI Challenges Pulmonary Delivery of Proteins and Peptides 9.6.3.3.2 Detirelix (LHRH Antagonist)... 

---